Haemonetics Corporation provided earnings guidance for the fiscal year 2023. For the period, the company expected Total revenue: 6 - 10%.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
85.44 USD | -0.90% | +2.41% | -0.05% |
Apr. 04 | Haemonetics Gets FDA Clearance for New TEG 6s Global Hemostasis-HN Cartridge | MT |
Apr. 04 | Haemonetics Corporation Receives FDA Clearance for New TEG®? 6s Global Hemostasis - HN Cartridge | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.05% | 4.38B | |
-3.17% | 185B | |
-3.94% | 107B | |
-5.37% | 67.55B | |
+9.24% | 54.6B | |
+17.04% | 47.42B | |
+3.86% | 42.24B | |
+5.95% | 28.24B | |
+0.48% | 26.42B | |
+12.40% | 25.66B |
- Stock Market
- Equities
- HAE Stock
- News Haemonetics Corporation
- Haemonetics Corporation Provides Earnings Guidance for the Fiscal Year 2023